West Family Investments Inc. Raises Holdings in Eli Lilly and Company $LLY

West Family Investments Inc. boosted its stake in Eli Lilly and Company (NYSE:LLY) by 193.4% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,395 shares of the company’s stock after buying an additional 2,897 shares during the quarter. Eli Lilly and Company makes up about 0.8% of West Family Investments Inc.’s holdings, making the stock its 19th biggest position. West Family Investments Inc.’s holdings in Eli Lilly and Company were worth $3,426,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of LLY. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter valued at $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter valued at about $27,000. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $31,000. Blume Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares in the last quarter. Finally, IMG Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $35,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,074.94 on Friday. The business has a 50-day moving average of $889.37 and a two-hundred day moving average of $799.23. The firm has a market capitalization of $1.02 trillion, a PE ratio of 70.26, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Berenberg Bank restated a “hold” rating and set a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. HSBC lifted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Cantor Fitzgerald increased their target price on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,047.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.